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TO THE EDITOR
We have developed a simple approach
(see Supplementary Data online for
the method) to analyze the differ-
ences in the gene expression profile
of atopic and healthy skins in order
to better characterize the skin changes
associated with atopic dermatitis
(AD). This method has enabled us to
define gene expression profiles related
to the pathogenesis of AD from micro-
abrasive samples, which, conseque-
ntly, are applicable in young children
(Table 1).
During the development of the skin
sampling method, we evaluated the
relative expression of various constitu-
tive genes of the epidermis or inflam-
matory genes, depending on the depth
level measured by transepidermal water
loss. Results showed that the expression
levels were not correlated with the
extent of abrasion and are thus inde-
pendent of the sampling depth.
Moreover, even in the presence of a
small quantity of mRNA, we have been
able to demonstrate variations in ex-
pression between xerotic and inflam-
matory areas of patients with AD and
the control population. In addition, the
extraction of mRNA from these samples
provides information about certain cell
types involved in the pathophysiolo-
gical process of AD. Thus, although
keratinocytes predominate and express
a number of inflammatory markers, we
were also able to demonstrate the
presence of lymphocytes (expression
of CD25 and CD45Ro) and dendritic
cells (expression of CD1b and langerin).
Conversely, we were unable to demon-
strate the presence of macrophages
(CD163) and neutrophils (myeloper-
oxidase; data not shown), the latter
probably being present in small quan-
tities relative to other cell types.
In this study we observed a decrease
in the expression of profilaggrin in
atopic skins. Several studies have de-
monstrated that two mutations of the
filaggrin gene are highly associated
with the development of AD, particu-
larly in patients who also exhibit
allergic problems and asthma (Palmer
et al., 2006). However, the filaggrin
deficiency resulting in abnormal barrier
function does not appear to be purely
genetic and can also be dependent on
acquired immunity. In fact, the devel-
opment of an antigen-specific Th2-type
immune response causes reductions
in filaggrin and ceramide syntheses,
which characterize the abnormalities
of skin barrier function observed in AD
patients (Man et al., 2008). In addi-
tion to the impaired skin barrier, other
mechanisms promoting potentially patho-
genic microbial colonization are postu-
lated, such as an epidermal immune
deficiency that is reportedly respon-
sible for insufficient expression of anti-
microbial peptides. In fact, levels of
expression of these peptides in psori-
asis are clearly higher than those
observed in AD, the latter being higher
than those observed in healthy subjects
(Gambichler et al., 2008; Harder et al.,
2010). In agreement with these data,
the proposed methodology enabled us
to show a higher expression of anti-
microbial peptide (HBD2, HBD3, and
LL37) in AD compared with healthy
samples. Conversely, the experience of
Leung’s group (Howell et al., 2006)
does not show any increase in hBD3m
RNA expression in AD patients com-
pared with healthy subjects. In fact, it
showed the opposite tendency.
In addition, the increased expression
of NF-kB observed at the inflammatory
sites of atopic patients highlights the
key role that this factor might have
in controlling the inflammatory pro-
cesses in AD. The same applies to the
increased expression in lesional areas
of IkB kinases, which phosphorylate
NF-kB inhibitory proteins (IkB), thereby
releasing NF-kB, which becomes active.
Activation of NF-kB thus induces the
transcription of genes of proinflamma-
tory cytokines, chemokines, adhesion
molecules, cyclooxygenase 2, and still
others (Barnes and Karin, 1997). These
results are consistent with the demon-
stration of a marked expression of IL-1b
proinflammatory cytokines and the ad-
hesion molecule ICAM1, as well as that
of cyclooxygenase 2, in the inflamma-
tory areas of AD patients.
On the other hand, the higher
expression of markers of Langerhans
cells (langerin) in the inflammatory
areas and of dendritic cells (CD1a and
CD1b) in the inflammatory and xerotic
areas of the AD population compared
with healthy subjects appears to con-
firm the crucial role of these antigen-
presenting cells in AD (Schuller et al.,
2001). This increase might reflect the
cooperation between the dendritic cell
presenting the antigen and expressing
stimulatory molecules such as CD80
and CD86 and the T lymphocyte
responding to it by polarizing toward
the Th2 type in atopic situations (Ham-
mad et al., 2001). The expression of
CD80 and CD86 is effectively higher
in inflammatory areas than in xerotic
areas in AD subjects.
The approach developed here once
again enables us to demonstrate a more
marked expression in the lesional areas
of AD subjects of the CD45RO recep-
tor, which is synthesized after activa-
tion of naive T lymphocytes and carried
by memory T cells. In addition, it is
important to note that the domicilia-
tion of T cells in inflammatory skin is
particularly affected by the secretion
of IL-31, which in turn induces a profile
of keratinocyte chemokine secretionAbbreviation: AD, atopic dermatitis
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Table 1. Gene expression profiles
Marker Lesional area Xerotic area Healthy
Profilaggrin 66.36±89.21* 52.93±45.75** 207.20±169.76
28.74 36.41 185.61
(6.66–383.82) (2.52–158.24) (10.36–629.89)
Antimicrobial peptides HBD2 50.51±35.21*** 29.29±28.33**,$$ 6.23±6.31
36.84 22.32 3.62
(8.60–132.24) (1.97–114.95) (0.12–17.99)
HBD3 39.93±31.01*** 20.83±15.63***,$$ 2.53±3.51
33.00 16.55 1.25
(7.10–136.69) (1.75–65.87) (0.01–11.74)
LL37 39.32±31.35*** 18.90±17.38$$ 4.23±3.80
30.50 18.11 2.10
(6.59–144.22) (0.18–63.61) (0.02–9.97)
Markers of inflammatory response NF-kB 48.01±26.57*** 24.98±22.58**,$$$ 6.87±9.90
41.52 16.57 2.57
(18.90–119.99) (2.07–85.76) (0.09–33.94)
IkBKB 25.04±16.18*** 13.08±10.25*,$$$ 6.02±6.20
21.13 12.53 5.12
(4.49–64.30) (1.65–38.05) (0.10–18.41)
Cox-2 31.39±29.3*** 10.05±13.7$$$ 5.12±4.25
21.85 4.63 3.28
(0.86–103.60) (0.08–61.88) (0.66–13.52)
IL-1b 270.01±303.96*** 71.11±129.73$$$ 14.22±13.84
180.27 13.65 8.52
(5.69–1240.41) (0.20–472.84) (1.85–45.29)
ICAM 29.22±23.89*** 12.68±15.39**,$$ 2.34±2.65
19.99 7.00 1.99
(5.16–99.14) (0.23–55.32) (0.10–9.05)
Dendritic cell markers Langerin 15.33±9.70*** 13.00±12.96 4.42±2.20
13.85 7.71 3.43
(3.42–38.96) (1.61–48.27) (1.81–8.21)
CD1a 42.42±27.57*** 30.06±25.24*** 3.13±4.62
37.57 22.32 1.54
(4.86–117.19) (1.96–89.02) (0.26–16.12)
CD1b 15.07±11.31*** 10.05±9.93** 2.55±4.61
12.35 5.26 0.70
(2.28–42.86) (0.26–37.83) (0.08–14.35)
CD80 24.67±24.38*** 11.02±16.67$$$ 3.60±3.01
18.64 4.38 2.53
(1.35–109.92) (0.25–57.85) (0.18–10.43)
CD86 60.37±33.88*** 25.49±27.2*,$$$ 4.84±3.52
Lymphocyte markers CD45Ro 17.20±14.04*** 9.80±19.30$ 1.63±2.38
13.96 2.73 0.83
(3.26–52.45) (0.02–68.43) (0.11–8.54)
CD25 509.43±361.63*** 277.32±343.51***,$ 15.08±14.90
Table 1 continued on the following page
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(CCL17 and CCL22), promoting the
migration of T cells toward the skin
(Dillon et al., 2004). In addition, IL-31
is also said to have a key role in the
development of the pruriginous reac-
tion, and its concentration is reported to
be correlated to the severity of AD
(Raap et al., 2008). The demonstration
of levels of expression of IL-31 in atopic
samples, and particularly in inflamma-
tory areas, in contrast to samples taken
from healthy subjects, are consistent
with this. In addition, the increased
expression of CD25 in inflammatory
areas suggests a recruitment of T regu-
latory cells, dependent on chemokines
secreted particularly by dendritic cells
or resulting from a marked polyclonal
expansion of T lymphocytes following
the action of staphylococcal superanti-
gens (Ou et al., 2004).
Exacerbation of inflammatory epi-
sodes is also said to be prompted by a
major local neurogenic phenomenon
related in particular to substance P and
to CGRP under the control of nerve
growth factor (Ostlere et al., 1995).
Other receptors such as the TRPV3
and TRPV4 ion channels recently stud-
ied in AD might contribute to the
pathophysiology of inflammation and
neurogenic perceptions, such as the
pruritus characteristic of this condition
(Bı´ro´ et al., 2007). Thus, the over-
expression of substance P, CGRP, and
TRPV3 channels in AD patients (xerotic
and inflammatory areas) would appear
to cause sensitization of the afferent
nerve fibers and increase pruriginous
manifestations.
Conversely, we have shown that the
expression levels of POMC (a precursor
molecule that after proteolysis releases
hormones such as a-melanocyte stimu-
lating hormone) and TRPV6 were
markedly reduced in AD subjects. This
reduction is very pronounced in inflam-
matory areas and might influence the
induction of episodes in AD. In fact,
several studies demonstrate the antag-
onistic action of a-melanocyte stimulat-
ing hormone on proinflammatory
cytokines IL-1a, IL-1b, IL-6, and tumor
necrosis factor-a (Bo¨hm et al., 2006)
Table 1. Continued
Marker Lesional area Xerotic area Healthy
436.46 146.73 9.52
(89.83–1,697.45) (2.77–1,542.18) (0.46–43.17)
IL-31 29.51±39.38*** 7.89±20.23**,$$ 0.00±0.00
14.56 0.42 0.00
(0.00–137.98) (0.00–89.63) (0.00–0.00)
Neuromediators and TRPV channels CALCA 10.68±12.44** 2.42±4.34**,$$ 0.00±0.00
6.89 0.44 0.00
(0.00–41.94) (0.00–15.03) (0.00–0.00)
TAC-1 26.63±23.86** 21.17±22.7** 6.61±12.31
20.98 13.67 1.20
(3.23–98.10) (1.35–97.97) (0.04–38.16)
POMC 6.35±5.74*** 8.48±8.05*** 164.62±205.07
4.71 5.96 80.21
(0.00–18.10) (0.00–33.05) (15.53–592.11)
TRPV3 27.17±21.79*** 12.79±12.73$$$ 6.3±8.57
23.95 7.86 3.37
(5.43–100.26) (2.12–47.36) (0.12–30.03)
TRPV4 38.38±30.68 27.16±50.48$$ 25.73±30.31
33.66 14.20 14.53
(1.47–137.05) (3.29–248.39) (3.12–97.43)
TRPV6 6.57±10.55** 25.15±49.72** 140.09±165.41
1.61 7.12 82.54
(0.00–34.95) (0.00–199.83) (7.93–475.47)
*Po0.0170, **Po0.01, ***Po0.001 versus healthy patients (Wilcoxon test).
$Po0.0170, $$Po0.01, $$$Po0.001 versus lesional area of atopic patients.
Student’s t-test has been used for the following markers: CD1a, CD1b, CD25, CD86, HBD2, NFKB, POMC, and TAC-1. In all the other cases, we have used
Wilcoxon test.
A Dunn–Sidak correction was made to adjust for the multiplicity of tests.
Median values are given in italics and ranges are indicated in parentheses.
www.jidonline.org 471
P Bianchi et al.
Gene Expression in Atopic Dermatitis
and also its inhibitory role in lympho-
cyte activation and function (Luger
et al., 1993). Similarly, the reduction
in TRPV6 expression in atopic subjects
might induce a reduction in the intra-
cellular calcium content and conse-
quently in disruption of the epidermal
proliferation/differentiation balance.
In conclusion, although none of
these factors are specific for AD, it is
still the case that together they provide
an aid to understanding the mecha-
nisms of the pathogenesis of AD.
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Impede Harmonization
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TO THE EDITOR
This letter is in response to a recent
article (Schmitt et al., 2011) and the
accompanying commentary (Flohr,
2011). The use of the term ‘‘eczema’’
would seem to be a step backward in the
process of ‘‘harmonizing’’ outcome
measures for atopic eczema/atopic
dermatitis (AD). We all recognize that
‘‘eczema’’ is a term used by our pati-
ents and by non-cognoscenti physi-
cians to indicate AD but it is nonspecific
and dermatologists know there are many
types of eczema that clearly are not AD.
In 2004, the World Allergy Organi-
zation (WAO) stated that the term
‘‘eczema’’ would include ‘‘non-atopic
eczema’’ and ‘‘atopic eczema,’’ the latter
being ‘‘eczema in a person of the atopic
constitution’’ (Johansson et al., 2004).
Atopy was defined as specific IgE (sIgE)
reactivity in high responders sensitized
via mucosal surfaces. This definition was
rendered dubious the next year by the
NHANES III study showing sIgE to
common allergens in 54% of the United
States population (Arbes et al., 2005) and
by numerous reports since 2006 indica-
ting that the transcutaneous route
may be a major pathway for IgE sensi-
tization (Weidinger et al., 2006; van den
Oord and Sheikh, 2009; Brown et al.,
2011). Infants often have typical disease
well before relevant sIgE levels. They do
not need testing to be properly diagnosed
as AD, which might well predispose to
atopy; routine sIgE tests are not usually
indicated (Boyce et al., 2010).Abbreviations: AD, atopic dermatitis; sIgE, specific IgE; WAO, World Allergy Organization
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